The risk of uveitis due to prostaglandin analogs in pediatric glaucoma.

To examine the incidence of uveitis in children prescribed prostaglandin analogs (PGAs) for glaucoma. In this dual-center cohort study, the medical records of consecutive patients <18 years old treated with a PGA between January 1, 2012, and December 31, 2018, were reviewed retrospectively. Patients with all forms of glaucoma, including those with a prior history of uveitis, were included. Patients who had been on a PGA prior to their first recorded visit were excluded. Patient charts were reviewed for new or recurrent uveitis during the first year of PGA therapy. A total of 103 children (147 eyes) were included, with a total PGA exposure of 1,352 child-months. Ninety-eight children (142 eyes) tolerated the PGA without an episode of uveitis. Five patients with a documented prior history of uveitis experienced a unilateral episode of uveitis. A review of their medical records identified prescribed or unscheduled decrease in topical steroids or immunosuppressive medication as the most likely cause of uveitis recurrence. This study provides further evidence that PGAs are unlikely to induce uveitis in children being treated for glaucoma and suggests that this may also be true in those with a history of uveitis. We are unable to evaluate whether PGAs make recurrence more likely or the tapering of steroids more difficult. Copyright © 2022 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Citation

Nicholas R Bello, Kara C LaMattina, Jade M Minor, Virginia Miraldi Utz, Kaylin Dong, Alex V Levin. The risk of uveitis due to prostaglandin analogs in pediatric glaucoma. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2022 Jun;26(3):126.e1-126.e5

Mesh Tags

Substances

PMID: 35550862

search → result